Product Description
Baricitinib is used alone or with other medications to treat rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) in adults who have not responded well to one or more tumor necrosis factor (TNF) inhibitor medication(s). Baricitinib is in a class of medications called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system. (Sourced from: https://medlineplus.gov/druginfo/meds/a618033.html)
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Alopecia|Alopecia Areata *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: Arthritis, Rheumatoid | Arthritis | COVID-19
Known Adverse Events: Embolism | Embolism and Thrombosis | Thrombosis | Thrombocytosis | Arthritis, Rheumatoid | Neutropenia | Respiratory Tract Infections | Urinary Tract Infections | Arthritis | Pulmonary Embolism | Herpes Simplex | Herpes Zoster
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ghana, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Korea, Mexico, Monaco, Nepal, Netherlands, New Zealand, Pakistan, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Slovenia, South Africa, Spain, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 56
Highest Development Phases
Phase 3: Aicardi Syndrome|Aicardi-Goutieres Syndrome|Alopecia Areata|Arthritis, Juvenile|Arthritis, Psoriatic|Arthritis, Rheumatoid|COVID-19|Dermatitis, Atopic|Hair Diseases|Hypotrichosis|Influenza, Human|Lipodystrophy|Lupus Erythematosus, Systemic|Pneumonia|STING-Associated Vasculopathy With Onset in Infancy|Severe Acute Respiratory Syndrome|Uveitis
Phase 2: Giant Cell Arteritis|Kidney Diseases|Kidney Failure, Chronic|Lichen Planus, Oral|Myositis|Polymyalgia Rheumatica|Psoriasis|Sjogren's Syndrome|Vitiligo
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JUVE-X | P3 |
Recruiting |
Arthritis, Juvenile |
2031-07-01 |
|
| I4V-MC-JAHX | P3 |
Unknown Status |
Arthritis, Juvenile |
2030-12-18 |
|
| I4V-MC-JAIO | P3 |
Unknown Status |
Alopecia Areata |
2029-10-01 |
|
| jRCT2051220189 | P3 |
Recruiting |
Alopecia Areata |
2029-09-30 |